Kissei Of Japan Asthma Drug In Trials In China, U.S. With MediciNova
This article was originally published in PharmAsia News
Executive Summary
Kissei Pharmaceutical of Japan is set to enter clinical trials in China and the United States for its MN-221 treatment for bronchial asthma